PACEpartners Inc. Announces Results of Annual and Special Meeting and Name Change to Vivione Biosciences Inc.

NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE
UNITED STATES


PACEpartners Inc. (TSX VENTURE:PIA) (the "Corporation") is pleased to announce
that shareholders overwhelmingly approved all resolutions placed before them by
management at the Corporation's annual and special meeting for Class A Common
and Class B Common shareholders (the "Shareholders"), which was held on July 18,
2013 (the "Meeting"). 


At the Meeting, a special resolution was passed to change the name of the
Corporation from PACEpartners Inc. to Vivione Biosciences Inc. The Corporation's
new ticker symbol will be "VBI" and trading under the new name and symbol will
begin on July 23, 2013. Kevin Kuykendall, Chief Executive Officer, commented:
"Since completing the merger with PACEpartners Inc. and funding of the maximum
$6 million raise on April 19, 2013, we are pleased that our Shareholders have
supported management's objectives at our first Shareholder meeting. We look
forward to executing our business strategy and building our corporate brand
under the new name Vivione Biosciences Inc. This new name better reflects the
nature of our business and will allow us to expand upon the existing
relationships our operating subsidiary, Vivione Biosciences, LLC, has
established with the scientific and business community."


Shareholders re-elected Kevin Kuykendall, Ted Moskal, Philip Tuttle, Lal Narang
and Ian Gallie as directors of the Corporation, and elected Glenn Smith and Dr.
James Hendren as new directors. The Corporation received shareholder approval of
its stock option plan and the Amended and Restated By-Law No.1 of the
Corporation, which was adopted by the board of directors on June 19, 2013. 


A special resolution was also passed at the Meeting approving an amendment to
the Corporation's Articles of Incorporation to include what are commonly
referred to as "coat-tail provisions" in the share structure of both the Class A
Common Shares and Class B Common Shares. The coat-tail provisions require that a
take-over bid offer (subject to certain qualifications) must be made to both the
holders of Class A Common Shares and Class B Common Shares, and cannot be made
to only one class of these common shares. In due course, the Corporation will
file a copy of its revised share structure on SEDAR, which can be obtained at
www.sedar.com. 


Business of the Corporation

The Corporation's business is centered on the commercialization of the RAPID-B
diagnostic system, which is an integrated system of hardware, software and
chemical reagents that tests bacteria in key environments. This technology could
have potentially diverse applicability from food safety to clinical diagnostics,
by identifying and quantifying microorganism levels more rapidly and with
greater precision than currently employed techniques.


FORWARD-LOOKING INFORMATION

This news release contains "forward-looking statements" within the meaning of
applicable securities laws. Although the Corporation believes that the
expectations reflected in its forward-looking statements are reasonable, such
statements have been based on factors and assumptions concerning future events
that may prove to be inaccurate. These factors and assumptions are based upon
currently available information to the Corporation. Such statements are subject
to known and unknown risks, uncertainties and other factors that could influence
actual results or events and cause actual results or events to differ materially
from those stated, anticipated or implied in the forward-looking statements. In
particular, this press release contains forward-looking information relating to
the expected date the Corporation will begin trading under a new name and ticker
symbol and the commercialization of RAPID-B. Readers are cautioned to not place
undue reliance on forward-looking statements. The statements in this press
release are made as of the date of this release and, except as required by
applicable law, the Corporation does not undertake any obligation to publicly
update or to revise any of the included forward-looking statements, whether as a
result of new information, future events or otherwise. The Corporation
undertakes no obligation to comment on analyses, expectations or statements made
by third-parties in respect of the Corporation or its financial or operating
results or (as applicable), its securities.


The securities mentioned herein have not been and will not be registered under
the United States Securities Act of 1933, as amended, or the securities laws of
any state, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements. This
press release does not constitute an offer to sell or the solicitation of any
offer to buy these securities in any jurisdiction.


NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM
IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY
FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Vivione Biosciences Inc.
Kevin Kuykendall
Chief Executive Officer
[phone]